Salut Kam,
Un peu en retard aujourd'hui mais CIC me donne des vacances. Pour INCY j'ai une news de samedi et une aujourd'hui :
Incyte Genomics, Inc.
N MARKET GUIDE INC
G
K Copyright (c) 2000, Market Guide Inc., All rights reserved
G TABLE OF CONTENTS
L
OUS;INCY[MG]/2 L<<< Company Description
OUS;INCY[MG]/3 L<<< Quarterly Summary
OUS;INCY[MG]/4 L<<< Company To Industry Ratio Comparison
OUS;INCY[MG]/5 L<<< Share Ownership & Price Performance
OUS;INCY[MG]/6 L<<< Capitalization, Officers & Address
OUS;INCY[MG]/7 L<<< Annual Income Statements
OUS;INCY[MG]/8 L<<< Annual Income Statements - Continued
OUS;INCY[MG]/9 L<<< Quarterly & Year To Date Income Statements
OUS;INCY[MG]/10 L<<< Annual & Quarterly Balance Sheets
OUS;INCY[MG]/11 L<<< Annual & Year To Date Statement of Cash Flows
G
G
G
OComplete Financials: G March 2000 OExchange G NASD
O G OFY END G DEC
L ISSUE DATA (06/16/00) PER SHARE DATA RATIOS
OPrice $ G 86.38 OEPS (TTM) $ G -1.15 OP/E (TTM) G NM
O52W High $ G 289.06 ODiv. Rate $ G 0.00 OYield G 0.00 %
O52W Low $ G 16.44 OBook Value $ G 19.00 OPrice/Book G 4.55
OShrs Out G 31.80 Mil OCash $ G 21.77 OROE (TTM) G -12.82 %
OFloat G 26.10 Mil ORev (TTM) $ G 5.57 OROA (TTM) G -9.27 %
OMon. Vol G 26.27 Mil O G OCurr. Ratio G 10.73
OBeta G 0.35 O G OLT Dbt/Eqty G 0.34
O BRIEF: G INCY designs, develops and markets genomic
G information based tools including database products, genomic
G data management software tools, microarray-based gene
G expression services and genomic reagents and related
G services. For the 3 months ended 3/00, revenues rose 8% to
G $40.8M. Net loss totalled $8.2M, up from $1.9M. Results
G reflect increased database and related product sales. Net
G loss reflects higher R&D, sales and marketing expenses.
G
G L HISTORICAL QUARTERLY RESULTS ($000)
LREVENUE 1997 1998 1999 2000
O1st Qtr MAR G 17,998 30,379 37,630 40,754
O2nd Qtr JUN G 21,425 33,093 37,893
O3rd Qtr SEP G 23,226 34,692 35,415
O4th Qtr DEC G 27,347 36,647 46,024
LEPS (U.S. Dollars per share)
O1st Qtr MAR G 0.020 0.120 -0.070 -0.270
O2nd Qtr JUN G 0.050 0.180 -0.260
O3rd Qtr SEP G 0.080 -0.250 -0.390
O4th Qtr DEC G 0.110 0.050 -0.220
G
G FY'94 - FY'96 restated for the 7/96 pooling w/Genome
G Systems. 7/96, issued 204,073 shrs. of Common for pooling.
G FY'97-'96 fincls restated for 1/98 polling w/Synteni.
G
L DIVIDENDS EMPLOYEES
O Last Dividend Decl. G $ NA O # Employees G 1,108
O Last Div Ex-Date G NA O Sales/Employee (TTM) G 144,482
O Last Div Pay Date G NA O Net. Income/Empl.(TTM G) NM
LCOMPANY COMPARISON TO THE BIOTECHNOLOGY AND S&P 500 AGGREGATES
LVALUATION RATIOS: COMPANY INDUSTRY S&P 500
OP/E Ratio G NM 55.45 35.47
ODividend Yield G 0.00 0.02 1.12
OPrice to Tangible Book G 4.65 17.61 12.58
OPrice to Book G 4.55 16.28 9.19
OPrice to Free Cash Flow G -33.41 71.71 46.99
LGROWTH STATISTICS:
O3 Yr Rev Growth G 55.31 30.59 16.82
O3 Yr EPS Growth G NM 26.85 18.39
O3 Yr Div Growth G NM -4.10 11.24
OReinvestment Rate G 100.00 99.99 75.40
LPROFITABILITY RATIOS:
ONet Profit Margin G -20.64 18.98 12.16
OReturn on Equity G -12.82 7.08 22.12
OInterest Coverage G -21.36 4.91 10.02
LFINANCIAL STRENGTH RATIOS:
OCurrent Ratio G 10.73 8.08 1.66
OLT Debt to Equity G 0.34 0.29 0.75
OTotal Debt to Equity G 0.34 0.32 0.94
L INSTITUTIONAL OWNERSHIP INSIDER TRADING (Prev. 6 months)
G O % Shares Out. Owned G 64.05 % ONet Insider Trades G -8
O # of Institutions G 287 O# Buy Transactions G 0
O Total Shs Held G 20.368 Mil O# Sell Transactions G 8
O 3 Mo. Net Purch. G 2.501 Mil ONet Shares Bought G-0.180 Mil
O 3 Mo. Shs Purch. G 7.660 Mil O# Shares Bought G 0.000 Mil
O 3 Mo. Shs Sold G 5.158 Mil O# Shares Sold G 0.180 Mil
G
O 4 Week Price % Change G 41.6% O 4 Week Rel. Price % Change G 37.6%
O 13 Week Price % Change G -41.0% O 13 Week Rel. Price % Change G -41.8%
O 26 Week Price % Change G 174.2% O 26 Week Rel. Price % Change G 163.1%
O 52 Week Price % Change G 267.6% O 52 Week Rel. Price % Change G 233.1%
OYTD Week Price % Change G 44.0% OYTD Week Rel. Price % Change G 43.0%
G
L SHORT INTEREST
O Current month G 1.069 Mil
O Previous month G 1.193 Mil
O Avg Daily Vol. G 0.873 Mil
G
LMARKET MAKERS: G NITE TSCO BTAB VECT MASH LEHM GMGS SHWD
OEQUITY: GCommon Stock $.001 Par, 3/00, 75M auth., 31,801,867 issd.
GInsiders control approx. 7%. Two others own approx. 11%.
GIPO 11/93, 2M shares @ $7.50 by D. Blech and Co. PO 11/95,
G1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs
G@ $67 by Hambrecht & Quist. 11/97, 2-for-1 stock split.
G*6/00, Name changed from Inccyte Pharmaceuticals, Inc.
G
OOFFICERS: G J.J. Collinson, Chmn., R.W. Scott, Pres./CSO/
GSecy., R.A. Whitfield, CEO, M.D. Lack, COO, John M. Vuko,
GCFO, T.G. Henn, VP-Fin./Contr./CAO. TRANSFER AGENT:
GChaseMellon Shareholder Services. Company incorporated 1991
Gin DE. Inquiries to: Director of Investor Relations.
O ADDRESS & PHONE NUMBERS
GIncyte Genomics, Inc.
G3174 Porter Drive
GPalo Alto, CA 94304
GPHONE: (650) 855-0555
G FAX: (650) 855-0572
G
G
LANNUAL INCOME STATEMENT ($000)
L 12M 12/31/96 12M 12/31/97 12M 12/31/98 12M 12/31/99
L RSTD12/31/98 RSTD12/31/98
OContract Revenue G 41,895 89,996 134,811 156,962
O Total Revenue G 41,895 89,996 134,811 156,962
OResearch/Development G 41,337 72,452 97,192 146,833
OGeneral/Admin. G 6,957 13,928 25,438 37,235
OIn-process R & D G 3,165 0 10,978 0
OAcquis.-Related Chrg G 0 0 1,171 0
O Total Expenses G 51,459 86,380 134,779 184,068
O Operating Income G -9,564 3,616 32 -27,106
LANNUAL INCOME STATEMENT ($000) (Contd.)
L 12M 12/31/96 12M 12/31/97 12M 12/31/98 12M 12/31/99
L RSTD12/31/98 RSTD12/31/98
O Operating Income G -9,564 3,616 32 -27,106
OInterest Expense G -250 -186 -150 -316
OOther, Net G 2,538 4,026 5,942 -146
O Income Before Taxes G -7,276 7,456 5,824 -27,568
OIncome Taxes G 0 548 2,352 -800
O Income After Taxes G -7,276 6,908 3,472 -26,768
O Pri/Bas EPS Ex. XOrd G -0.325 0.284 0.129 -0.951
O Pri/Bas EPS In. XOrd G -0.325 0.284 0.129 -0.951
OPrimary/Basic Avg Sh G 22,398.00 24,300.00 26,921.00 28,138.00
OCommon Dividends/Shr G 0.0000 0.0000 0.0000 0.0000
LSELECTED INCOME STATEMENT ITEMS ($000)
L QUARTERS YEAR TO DATE
L 3M 03/31/99 3M 03/31/00 3M 03/31/99 3M 03/31/00
ORevenue G 37,630 40,754 37,630 40,754
OOperating Expenses G 39,623 56,155 39,623 56,155
O Operating Income G -1,993 -15,401 -1,993 -15,401
ONon-Operating Income G 221 9,121 221 9,121
ONon-Operating Expenses G -138 -1,897 -138 -1,897
O Income Before Taxes G -1,910 -8,177 -1,910 -8,177
OIncome Taxes G 0 0 0 0
OAdjustments to Income G 0 0 0 0
O Inc. for Primary EPS G -1,910 -8,177 -1,910 -8,177
O Pri/Bas EPS Ex. XOrd G -0.069 -0.270 -0.069 -0.270
ODisc Opns + Xord Items G 0 0 0 0
O Pri/Bas EPS In. XOrd G -0.069 -0.270 -0.069 -0.270
OPrimary/Basic Avg Sh G 27,879.00 30,306.00 27,879.00 30,306.00
O Dilutd EPS Excl XOrd G -0.069 -0.270 -0.069 -0.270
O Dilutd EPS Incl XOrd G -0.069 -0.270 -0.069 -0.270
OCommon Dividends/Shr G 0.000 0.000 0.000 0.000
LSELECTED BALANCE SHEET ITEMS ($000)
L YEAR ENDING QUARTER ENDING
L 12/31/98 12/31/99 03/31/99 03/31/00
OCash & ST Investments G 111,233 66,937 133,730 692,154
OReceivables G 14,318 26,608 9,713 14,368
O Total Current Assets G 131,364 109,501 148,985 728,940
OLT Investments G 20,653 19,275 19,042 41,272
OFixed Assets G 54,429 67,293 58,616 73,562
O Total Assets G 230,290 221,934 250,755 875,692
OAccounts Payable G 8,244 6,501 6,493 11,903
OST Debt & Curr LTD G 0 0 0 0
O Total Current Liab. G 49,927 51,458 72,633 67,949
OLT Debt & Cap Leases G 796 194 549 203,423
O Total Liabilities G 50,723 51,652 73,182 271,372
OPreferred Stock G 0 0 0 0
OCommon/Paid In Capital G 209,220 222,834 209,588 641,905
ORetained Earnings G -28,401 -55,169 -30,311 -63,346
O Total Equity G 179,567 170,282 177,573 604,320
OShares Outstanding G 27,830 28,890 27,912 31,802
LSELECTED STMT OF CASH FLOWS - INDIRECT METHOD ($000)
L ANNUAL YEAR TO DATE
L 12M 12/31/98 12M 12/31/99 3M 03/31/99 3M 03/31/00
ONet Income G 3,472 -26,768 -1,910 -8,177
ODepreciation & Amort. G 17,827 24,688 6,029 8,114
ONon Cash Items G 12,730 5,390 1,376 -4,134
O Total Operating CF G 36,233 -21,446 31,662 17,119
OCapital Expenditures G -30,710 -34,758 -8,927 -12,490
O Total Investing CF G -45,363 -8,684 1,907 -243,626
ODividends Paid G 0 0 0 0
OSale (Purch.) of Stock G 4,749 13,614 368 419,262
ONet Borrowings G -781 -1,160 -289 196,337
O Total Financing CF G 3,984 12,467 79 615,619
OExchange Rate Effect G -404 -165 -150 2
ONet Change In Cash G -5,550 -17,828 33,498 389,114
OOper CF-Cap Exp-Div Pd G 5,523 -56,204 22,735 4,629
KCopyright (c) 2000, Market Guide Inc., All rights reserved
G
Jun-17-2000 16:07 GMT
Symbols:
US;INCY
Source B Market Guide
DJ Insider Sells INCYTE GENOMICS INC (INCY)
SOURCE: Form 4
ISSUER: INCYTE GENOMICS INC
SYMBOL: INCY
FILER: BENDEKGEY ELLAS
TITLE: Vice President
TRANSACTION: Sale 12,500 05/03/00 $73.00
OWNERSHIP: ZERO
The Form 4 is filed with the Securities and Exchange Commission by any
insider buying or selling their company's shares. This form must be
filed by the 10th of the month following the month in which the
transaction was executed.
Insider data provided by: Washington Service 202/778-1380 or www.washserv.com
(END) DOW JONES NEWS 06-19-00
12:12 AM- - 12 12 AM EDT 06-19-00
Jun-19-2000 04:24 GMT
Symbols:
US;INCY
Source DJ Dow Jones
Categories:
I/BTC I/MTC SUB/DJN N/DJN SUB/DJWI N/DJWI SUB/ISD N/ISD SUB/WSV N/WSV
SUB/DJWB N/DJWB M/NND M/TEC P/DPH GEO/CAL R/CAL GEO/NME R/NME GEO/PRM R/PRM
GEO/US R/US GEO/USW R/USW
Pallmer |
